CIK 1952142
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 92.97% | 61 |
| Unclassified | 3.25% | 5 |
| Life Sciences Tools & Services | 2.02% | 1 |
| Health Care Providers & Services | 1.52% | 2 |
| Health Care Equipment & Supplies | 0.23% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | SRRK | Scholar Rock Holding Corp | Health Care | 9.86% |
| 2 | ABVX | Abivax S.A. | Health Care | 6.77% |
| 3 | SNDX | Syndax Pharmaceuticals Inc | Health Care | 5.50% |
| 4 | RVMD | Revolution Medicines, Inc. | Health Care | 5.30% |
| 5 | IMVT | Immunovant, Inc. | Health Care | 3.59% |
| 6 | PRAX | Praxis Precision Medicines, Inc. | Health Care | 3.51% |
| 7 | MBX | MBX Biosciences, Inc. | Health Care | 2.89% |
| 8 | MLYS | Mineralys Therapeutics, Inc. | Health Care | 2.80% |
| 9 | ELVN | Enliven Therapeutics, Inc. | Health Care | 2.76% |
| 10 | CGON | CG Oncology, Inc. | Health Care | 2.70% |
65/70 names classified · sector 96.7% of weight · industry 96.7% · mkt cap 90.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 96.7% of the book is sector-classified (unclassified names shown, never dropped).
Only 3% of book weight classified — the grid is NOT representative of the whole book.
Classified: 3.2% of book weight (5/70 names) · unclassified 96.8%: SRRK, ABVX, SNDX, RVMD, IMVT, PRAX, MBX, MLYS, ELVN, CGON +55 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | SRRKSCHOLAR ROCK HLDG CORP | 2,070,992 | $102M | 9.9% | ADD 134% |
| 2 | ABVXABIVAX SA | 627,582 | $70M | 6.8% | ADD 60% |
| 3 | SNDXSYNDAX PHARMACEUTICALS INC | 2,431,486 | $57M | 5.5% | ADD 82% |
| 4 | RVMDREVOLUTION MEDICINES INC | 563,264 | $55M | 5.3% | ADD 808% |
| 5 | IMVTIMMUNOVANT INC | 1,492,988 | $37M | 3.6% | ADD 131% |
| 6 | PRAXPRAXIS PRECISION MEDICINES I | 112,534 | $36M | 3.5% | ADD 434% |
| 7 | MBXMBX BIOSCIENCES INC | 998,938 | $30M | 2.9% | ADD 1172% |
| 8 | MLYSMINERALYS THERAPEUTICS INC | 1,066,756 | $29M | 2.8% | ADD 268% |
| 9 | ELVNENLIVEN THERAPEUTICS INC | 726,876 | $28M | 2.8% | NEW |
| 10 | CGONCG ONCOLOGY INC | 411,244 | $28M | 2.7% | NEW |
| 11 | BHVNBIOHAVEN LTD | 3,188,982 | $27M | 2.6% | NEW |
| 12 | ROIVROIVANT SCIENCES LTD | 771,600 | $21M | 2.1% | TRIM −20% |
| 13 | EYPTEYEPOINT INC | 1,621,528 | $21M | 2.0% | ADD 358% |
| 14 | ARQTARCUTIS BIOTHERAPEUTICS INC | 827,584 | $19M | 1.9% | ADD 268% |
| 15 | GPCRSTRUCTURE THERAPEUTICS INC | 400,534 | $19M | 1.9% | ADD 14% |
| 16 | SRZNSURROZEN INC | 721,620 | $19M | 1.9% | ADD 16% |
| 17 | AMLXAMYLYX PHARMACEUTICALS INC | 1,339,370 | $19M | 1.8% | ADD 137% |
| 18 | DYNDYNE THERAPEUTICS INC | 1,012,150 | $18M | 1.8% | ADD 21% |
| 19 | EWTXEDGEWISE THERAPEUTICS INC | 581,728 | $18M | 1.8% | ADD 61% |
| 20 | CYTKCYTOKINETICS INC | 259,154 | $17M | 1.7% | ADD 76% |
| 21 | SYRESPYRE THERAPEUTICS INC | 335,212 | $17M | 1.6% | ADD 935% |
| 22 | DNLIDENALI THERAPEUTICS INC | 853,122 | $16M | 1.6% | ADD 104% |
| 23 | XENEXENON PHARMACEUTICALS INC | 281,510 | $16M | 1.6% | TRIM −19% |
| 24 | CLDXCELLDEX THERAPEUTICS INC NEW | 508,534 | $16M | 1.6% | NEW |
| 25 | PTGXPROTAGONIST THERAPEUTICS INC | 145,154 | $15M | 1.5% | ADD 144% |
| 26 | TYRATYRA BIOSCIENCES INC | 386,354 | $15M | 1.4% | NEW |
| 27 | DNTHDIANTHUS THERAPEUTICS INC | 171,004 | $14M | 1.4% | ADD 116% |
| 28 | CELCCELCUITY INC | 120,124 | $14M | 1.3% | HOLD |
| 29 | DFTXDEFINIUM THERAPEUTICS INC COM SHS | 650,966 | $12M | 1.2% | NEW |
| 30 | BIOABIOAGE LABS INC | 677,308 | $12M | 1.1% | NEW |
| 31 | NAMSNEWAMSTERDAM PHARMA COMPANY | 361,316 | $12M | 1.1% | ADD 394% |
| 32 | ACADACADIA PHARM | 485,132 | $11M | 1.0% | NEW |
| 33 | ASMBASSEMBLY BIOSCIENCES INC | 370,870 | $10M | 1.0% | ADD 137% |
| 34 | ALMSALUMIS INC | 459,132 | $10M | 1.0% | NEW |
| 35 | NRIXNURIX THERAPEUTICS INC | 630,452 | $10M | 0.9% | NEW |
| 36 | ZURAZURA BIO LTD | 1,507,040 | $9M | 0.9% | NEW |
| 37 | EVMNEVOMMUNE INC | 387,554 | $9M | 0.8% | ADD 468% |
| 38 | TNGXTANGO THERAPEUTICS INC | 401,838 | $8M | 0.8% | NEW |
| 39 | FTHSENSEI BIOTHERAPEUTICS INC | 265,746 | $8M | 0.8% | NEW |
| 40 | RLMDRELMADA THERAPEUTICS INC | 1,194,818 | $8M | 0.8% | NEW |
| 41 | ERASERASCA INC | 479,722 | $8M | 0.8% | NEW |
| 42 | JNJJOHNSON & JOHNSON | 30,830 | $8M | 0.7% | TRIM −12% |
| 43 | XFORX4 PHARMACEUTICALS INC | 1,701,484 | $7M | 0.7% | ADD 89% |
| 44 | PCVXVAXCYTE INC | 118,122 | $7M | 0.7% | NEW |
| 45 | WHWKWHITEHAWK THERAPEUTICS INC | 1,878,738 | $6M | 0.6% | ADD 29% |
| 46 | HLXCHELIX ACQUISITION CORP III | 610,056 | $6M | 0.6% | NEW |
| 47 | TENXTENAX THERAPEUTICS INC | 377,400 | $6M | 0.6% | NEW |
| 48 | ALKSALKERMES PLC | 160,984 | $6M | 0.6% | NEW |
| 49 | PHVSPHARVARIS N V | 173,274 | $5M | 0.5% | ADD 197% |
| 50 | IVVDINVIVYD INC | 3,749,092 | $5M | 0.5% | ADD 279% |
| 51 | JBIOJADE BIOSCIENCES INC | 308,068 | $4M | 0.4% | NEW |
| 52 | TWSTTWIST BIOSCIENCE CORP | 86,220 | $4M | 0.4% | TRIM −83% |
| 53 | MPLTMAPLIGHT THERAPEUTICS INC | 200,000 | $4M | 0.4% | ADD 100% |
| 54 | AVTXAVALO THERAPEUTICS INC | 269,484 | $4M | 0.4% | ADD 99% |
| 55 | IONSIONIS PHARMACEUTICALS INC | 52,770 | $4M | 0.4% | NEW |
| 56 | IMCRIMMUNOCORE HLDGS PLC | 127,086 | $4M | 0.4% | NEW |
| 57 | FBRXFORTE BIOSCIENCES INC | 116,040 | $3M | 0.3% | NEW |
| 58 | SIONSIONNA THERAPEUTICS INC | 73,080 | $3M | 0.3% | NEW |
| 59 | SABSSAB BIOTHERAPEUTICS INC | 750,000 | $3M | 0.3% | ADD 412% |
| 60 | SLDBSOLID BIOSCIENCES INC | 390,806 | $3M | 0.3% | NEW |
| 61 | LPCNLIPOCINE INC NEW | 320,840 | $3M | 0.2% | NEW |
| 62 | QUREUNIQURE NV | 156,132 | $3M | 0.2% | ADD 259% |
| 63 | LBRXLB PHARMACEUTICALS INC | 100,000 | $2M | 0.2% | NEW |
| 64 | CCCCC4 THERAPEUTICS INC | 906,472 | $2M | 0.2% | NEW |
| 65 | EWEDWARDS LIFESCIENCES CORP | 29,176 | $2M | 0.2% | NEW |
| 66 | CAPRCAPRICOR THERAPEUTICS INC | 75,184 | $2M | 0.2% | ADD 321% |
| 67 | BDSXBIODESIX INC | 140,008 | $2M | 0.2% | NEW |
| 68 | STROSUTRO BIOPHARMA INC | 46,590 | $1M | 0.1% | NEW |
| 69 | SPRBSPRUCE BIOSCIENCES INC | 12,720 | $831,252 | 0.1% | NEW |
| 70 | VTGNVISTAGEN THERAPEUTICS INC | 1,233,498 | $116,374 | 0.0% | ADD 100% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| SRRKSCHOLAR ROCK HLDG CORP | 166K | 566K | 528K | 726K | 887K | 2.1M | $102M |
| ABVXABIVAX SA | — | — | 88K | 166K | 392K | 628K | $70M |
| SNDXSYNDAX PHARMACEUTICALS INC | 2.9M | 1.6M | 2.4M | 1.4M | 1.3M | 2.4M | $57M |
| RVMDREVOLUTION MEDICINES INC | 194K | 319K | — | 185K | 62K | 563K | $55M |
| IMVTIMMUNOVANT INC | 1.1M | 853K | 1.3M | 1.6M | 645K | 1.5M | $37M |
| PRAXPRAXIS PRECISION MEDICINES I | 134K | — | 32K | — | 21K | 113K | $36M |
| MBXMBX BIOSCIENCES INC | — | 97K | 141K | 75K | 79K | 999K | $30M |
| MLYSMINERALYS THERAPEUTICS INC | 400K | — | 632K | 158K | 290K | 1.1M | $29M |
| ELVNENLIVEN THERAPEUTICS INC | 97K | 120K | — | — | — | 727K | $28M |
| CGONCG ONCOLOGY INC | — | 290K | — | 63K | — | 411K | $28M |
| BHVNBIOHAVEN LTD | 186K | 251K | 175K | 1.0M | — | 3.2M | $27M |
| ROIVROIVANT SCIENCES LTD | 2.7M | 2.6M | 602K | 4.2M | 967K | 772K | $21M |
| EYPTEYEPOINT INC | 580K | — | 329K | — | 354K | 1.6M | $21M |
| ARQTARCUTIS BIOTHERAPEUTICS INC | 501K | 440K | 206K | 412K | 225K | 828K | $19M |
| GPCRSTRUCTURE THERAPEUTICS INC | — | — | — | 129K | 351K | 401K | $19M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
